The Japan Hepatobiliary Pancreatic Oncology Network (JON-HBP)
At the fifth anniversary of our incorporated association


Our group, JON-HBP, was established in January 2021, to conduct clinical trials and research, and to encourage communication among experts, hospitals, academic conferences, and companies engaged in the field of Hepatobiliary Pancreatic Oncology, not only in Japan, but also around the world.

We appreciate the cooperation extended to us by many colleagues, researchers, institutes, companies, etc. I was the first Chair of our group, while Prof. Nagano took over and executed the role from April 2022 to March 2025. We have watched the group make various advances during the course of these 4 years of its existence. I wish to express my appreciation to Prof. Nagano for his expert management of JON-HBP.

Currently, as of March 2025, 84 institutes, including 1,092 researchers, 4 individual members, and 24 supporting companies, are affiliated to our group. We have gradually established, 6 committees, an accounting audit, a secretariat, and a data center. We shall strive to continually update these departments.

Our main mission is to conduct clinical trials and disseminate new evidence on cancer treatments to the world. To date, we have conducted/planned 23 trials, and reported the results of 5 trials in international conferences or medical journals.

Another important mission of our group is to hold update seminars on Hepatobiliary and pancreatic cancer, to allow latest information about the cancer to be discussed and shared. The seminars are held online twice a year, in the winter and summer, and about 300 persons participate in every seminar.
The year 2025 is the fifth year since our group was established. Our international committee has launched new international activities; face-to-face meetings with foreign researchers have been held to exchange opinions about the current status and future prospects in hepatobiliary and pancreatic oncology. We have also begun to provide grants to our young researchers to participate in international conferences.
We propose to continue to contribute with enthusiasm to advances in the development of cancer medicines in the future. We look forward to your continued cooperation and support.

May 2025
JON-HBP Chair
Junji Furuse, M.D., Ph.D.